This trial is testing a new cancer drug to see if it is safe and effective.
- Advanced Solid Tumors
2 Primary · 3 Secondary · Reporting Duration: From Day 1 until disease progression or Day 28, whichever came first
Awards & Highlights
1 Treatment Group
1 of 1
36 Total Participants · 1 Treatment Group
Primary Treatment: ABL503 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2021. "This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04762641.
Frequently Asked Questions
How many participants have been accepted into this scientific experiment?
"To complete the research at hand, 36 suitable candidates must take part in this experiment. People can sign up through NEXT Oncology, located in San Antonio Texas or Sarah Cannon Research Institute at HealthONE which is found in Denver Colorado." - Anonymous Online Contributor
Is this clinical research endeavor currently recruiting participants?
"Correct. According to clinicaltrials.gov, this medical study began recruiting participants on April 1st 2021 and is presently seeking volunteers for enrollment. The investigation requires 36 individuals from 5 distinct healthcare facilities." - Anonymous Online Contributor
How hazardous is ABL503 for human consumption?
"Since ABL503 is only in its inaugural trial, the safety rating was evaluated as a 1 due to limited evidence of efficacy and security." - Anonymous Online Contributor
Are there any hospitals in North America conducting this research initiative?
"Patients have the option of enrolling in this trial at 5 separate medical facilities: NEXT Oncology, Sarah Cannon Research Institute, City of Hope Duarte and 2 other sites." - Anonymous Online Contributor